SAM-e
SAM-e has more RCT support than most mood supplements, but Cochrane found the evidence low quality and inconclusive; it is expensive, unstable, and carries a genuine risk of triggering mania in people with bipolar disorder.
What the science says
- Antidepressant evidence is real but inconclusive Moderate evidence
A Cochrane review of 8 trials in 934 adults found no clear difference between SAM-e and placebo as monotherapy, and no difference versus imipramine or escitalopram, though one trial of SAM-e added to an SSRI showed benefit. The reviewers rated the evidence low quality and concluded it is insufficient to support routine clinical use.
- Osteoarthritis benefit is small and probably not clinically meaningful Limited evidence
A Cochrane review of 4 trials in 656 participants with knee or hip osteoarthritis found effects of SAM-e on pain and function that were small and did not reach clinical relevance, with wide confidence intervals. The often-quoted claim that SAM-e matches NSAIDs comes from underpowered comparisons.
- Mechanism is methyl donation, which cuts both ways Moderate evidence
SAM-e is the body's principal methyl donor, supporting monoamine synthesis, phospholipid methylation and glutathione production via transsulfuration. This same activity means adequate B12 and folate status is needed to recycle homocysteine, and deficiency in either can blunt the effect or raise homocysteine.
Dosage & safety
Scientific references
Where to buy
Vitacost, Synergy®, SAM-e, 400 mg, 30 Enteric Coated Tablets
View on iHerbReferral link — this site may earn a commission on purchases.
Related in Stress & mood
- Ashwagandha Moderate evidence
- L-Methylfolate Limited evidence
- 5-HTP Limited evidence
- L-Ornithine Limited evidence
- Rhodiola Rosea Limited evidence
- Eleuthero (Siberian Ginseng) Limited evidence